CSL Limited (ASX: CSL; OTCQX: CSLLY), a prominent global biotech company, has successfully transitioned from the Pink market to the OTCQX, enhancing transparency for U.S. investors. Upgrading to the OTCQX Market is a significant milestone, as it allows companies listed on qualified international exchanges through Cross-Trading to leverage their home market reporting to provide information to U.S. investors while adhering to streamlined market standards.
About CSL Limited
CSL, a global biotech leader, offers a diverse range of life-saving medicines for conditions like haemophilia, immune deficiencies, and influenza prevention. Through its three businesses, CSL Behring, CSL Seqirus, and CSL Vifor, the company delivers life-saving products to patients in over 100 countries, employing 30,000 individuals. Combining commercial strength, research and development focus, and operational excellence, CSL continually strives to innovate and empower patients to live their lives to the fullest.
